$GHST
GHST World Inc.

2024 Q4 Form 10-Q Financial Statement

#000107997324001544 Filed on November 14, 2024

View on sec.gov

Income Statement

Concept 2024 Q4 2024 Q3
Revenue $45.73K
YoY Change 91.82%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin
YoY Change
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $58.45K
YoY Change -25.86%
Operating Profit
YoY Change
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net $0.00
YoY Change -100.0%
Pretax Income
YoY Change
Income Tax
% Of Pretax Income
Net Earnings -$12.72K
YoY Change -77.33%
Net Earnings / Revenue -27.81%
Basic Earnings Per Share $0.00
Diluted Earnings Per Share $0.00
COMMON SHARES
Basic Shares Outstanding 130.2M shares 130.2M shares
Diluted Shares Outstanding 130.2M shares

Balance Sheet

Concept 2024 Q4 2024 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments
YoY Change
Cash & Equivalents $2.168K
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory
Prepaid Expenses
Receivables $0.00
Other Receivables
Total Short-Term Assets $2.168K
YoY Change -87.98%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets $2.168K
Total Long-Term Assets $0.00
Total Assets $2.168K
YoY Change -87.98%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable
YoY Change
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $323.2K
YoY Change 65.18%
LONG-TERM LIABILITIES
Long-Term Debt
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $323.2K
Total Long-Term Liabilities
Total Liabilities
YoY Change
SHAREHOLDERS EQUITY
Retained Earnings -$13.89M
YoY Change 3.48%
Common Stock $130.2K
YoY Change 3.56%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$321.0K
YoY Change
Total Liabilities & Shareholders Equity $2.168K
YoY Change -87.98%

Cashflow Statement

Concept 2024 Q4 2024 Q3
OPERATING ACTIVITIES
Net Income -$12.72K
YoY Change -77.33%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$45.17K
YoY Change 4.32%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities $29.04K
YoY Change 158.29%
NET CHANGE
Cash From Operating Activities -$45.17K
Cash From Investing Activities
Cash From Financing Activities $29.04K
Net Change In Cash -$16.13K
YoY Change -49.67%
FREE CASH FLOW
Cash From Operating Activities -$45.17K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2024Q3 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--06-30
CY2024Q3 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2025
CY2024Q3 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2024Q3 dei Entity Central Index Key
EntityCentralIndexKey
0001121795
CY2024Q3 dei Document Type
DocumentType
10-Q
CY2024Q3 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2024Q3 dei Document Period End Date
DocumentPeriodEndDate
2024-09-30
CY2024Q3 dei Document Transition Report
DocumentTransitionReport
false
CY2024Q3 dei Entity File Number
EntityFileNumber
000-31705
CY2024Q3 dei Entity Registrant Name
EntityRegistrantName
GHST World Inc.
CY2024Q3 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2024Q3 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
91-2007477
CY2024Q3 dei Entity Address Address Line1
EntityAddressAddressLine1
667 Madison Avenue
CY2024Q3 dei City Area Code
CityAreaCode
212
CY2024Q3 dei Local Phone Number
LocalPhoneNumber
634-6860
CY2024Q3 us-gaap Cash
Cash
2168 usd
CY2024Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
0 usd
CY2024Q3 us-gaap Assets Current
AssetsCurrent
2168 usd
CY2024Q3 us-gaap Assets
Assets
2168 usd
CY2024Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
14707 usd
CY2024Q3 GHST Due To Related Party Current
DueToRelatedPartyCurrent
298893 usd
CY2024Q3 GHST Common Stock Payable
CommonStockPayable
9559 usd
CY2024Q3 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
0 usd
CY2024Q3 us-gaap Liabilities Current
LiabilitiesCurrent
323159 usd
CY2024Q3 us-gaap Common Stock Value
CommonStockValue
130201 usd
CY2024Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
13443466 usd
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-13894666 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
-320991 usd
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
2168 usd
CY2024Q3 us-gaap Revenues
Revenues
45732 usd
CY2023Q3 us-gaap Revenues
Revenues
23841 usd
CY2024Q3 dei Entity Address City Or Town
EntityAddressCityOrTown
New York
CY2024Q3 dei Entity Address State Or Province
EntityAddressStateOrProvince
NY
CY2024Q3 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
10065
CY2024Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2024Q3 dei Entity Address Address Line2
EntityAddressAddressLine2
5th Floor
CY2024Q3 dei Entity Current Reporting Status
EntityCurrentReportingStatus
No
CY2024Q3 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2024Q3 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2024Q3 dei Entity Small Business
EntitySmallBusiness
true
CY2024Q3 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2024Q3 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2024Q3 dei Entity Shell Company
EntityShellCompany
false
CY2024Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
130201179 shares
CY2024Q2 us-gaap Cash
Cash
18302 usd
CY2024Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
3749 usd
CY2024Q2 us-gaap Assets Current
AssetsCurrent
22051 usd
CY2024Q2 us-gaap Assets
Assets
22051 usd
CY2024Q2 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
13814 usd
CY2024Q2 GHST Due To Related Party Current
DueToRelatedPartyCurrent
269854 usd
CY2024Q2 GHST Common Stock Payable
CommonStockPayable
9559 usd
CY2024Q2 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
37098 usd
CY2024Q2 us-gaap Liabilities Current
LiabilitiesCurrent
330325 usd
CY2024Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2024Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2024Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2024Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000 shares
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000 shares
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
130201179 shares
CY2024Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
130201179 shares
CY2024Q2 us-gaap Common Stock Value
CommonStockValue
130201 usd
CY2024Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
13443466 usd
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-13881949 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
-308274 usd
CY2024Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
22051 usd
CY2024Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
51766 usd
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
78841 usd
CY2024Q3 GHST Patent Development Costs
PatentDevelopmentCosts
6683 usd
CY2024Q3 us-gaap Operating Expenses
OperatingExpenses
58449 usd
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
78841 usd
CY2024Q3 us-gaap Other Income
OtherIncome
0 usd
CY2023Q3 us-gaap Other Income
OtherIncome
-1095 usd
CY2024Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
0 usd
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1095 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-12717 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-56095 usd
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.00
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.00
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.00
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.00
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
130201179 shares
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
125725003 shares
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
130201179 shares
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
125725003 shares
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-121513 usd
CY2023Q3 us-gaap Profit Loss
ProfitLoss
-56095 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-177608 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
-308274 usd
CY2024Q3 us-gaap Profit Loss
ProfitLoss
-12717 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
-320991 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-12717 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-56095 usd
CY2024Q3 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-3749 usd
CY2023Q3 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
6348 usd
CY2024Q3 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-0 usd
CY2023Q3 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
4253 usd
CY2024Q3 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
893 usd
CY2023Q3 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
29867 usd
CY2024Q3 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-37098 usd
CY2023Q3 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-6473 usd
CY2024Q3 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-45173 usd
CY2023Q3 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-43302 usd
CY2024Q3 us-gaap Proceeds From Repayments Of Related Party Debt
ProceedsFromRepaymentsOfRelatedPartyDebt
29039 usd
CY2023Q3 us-gaap Proceeds From Repayments Of Related Party Debt
ProceedsFromRepaymentsOfRelatedPartyDebt
11243 usd
CY2024Q3 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
29039 usd
CY2023Q3 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
11243 usd
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-16134 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-32059 usd
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
18302 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
39495 usd
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
2168 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
7436 usd
CY2024Q3 us-gaap Interest Paid Net
InterestPaidNet
0 usd
CY2023Q3 us-gaap Interest Paid Net
InterestPaidNet
0 usd
CY2024Q3 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0 usd
CY2023Q3 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-12717 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-56095 usd
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-13894666 usd
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-13426760 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
-320991 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-177608 usd
CY2024Q3 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-45173 usd
CY2023Q3 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-43302 usd
CY2024Q3 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p id="xdx_840_eus-gaap--ConcentrationRiskCreditRisk_zZ2gtwXNBe1h" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span id="xdx_863_z6aO04w0uBC">Concentration</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company’s financial instruments that are exposed to concentrations of credit risk primarily consist of its cash. The Company places its cash with financial institutions of high credit worthiness. At times, its cash with a particular financial institution may exceed any applicable government insurance limits. The Company’s management plans to assess the financial strength and credit worthiness of any parties to which it is a credit counterparty, and as such, it believes that any associated credit risk exposures are limited.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company currently receives all its revenues from two customers and all the deferred revenues from a few other customers. The Company has depended on a related party for short term funding, who provided a significant portion of the funding through September 30, 2024.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"> </p>
CY2024Q3 us-gaap Use Of Estimates
UseOfEstimates
<p id="xdx_841_eus-gaap--UseOfEstimates_zStn4PsnECO" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span id="xdx_86B_zn1GMLtXNbb7">Use of Estimates</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Such estimates and assumptions impact, among others, the following: fair value of share-based payments and deferred taxes.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from estimates.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"><b></b></p>
CY2024Q3 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
0 usd
CY2023Q3 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
0 usd
CY2024Q3 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
0 usd
CY2023Q3 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
0 usd
CY2024Q3 us-gaap Fair Value Asset Liability Recurring Basis Still Held Unrealized Gain Loss
FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLoss
0 usd
CY2023Q3 us-gaap Fair Value Asset Liability Recurring Basis Still Held Unrealized Gain Loss
FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLoss
0 usd
CY2024Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
0 shares
CY2023Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
0 shares
CY2021Q3 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
1-for-100
CY2024Q3 GHST Common Stock Payable
CommonStockPayable
9559 usd
CY2023Q3 GHST Common Stock Payable
CommonStockPayable
9559 usd
CY2024Q3 GHST Due To Related Party Current And Noncurrent
DueToRelatedPartyCurrentAndNoncurrent
298893 usd
CY2024Q2 GHST Due To Related Party Current And Noncurrent
DueToRelatedPartyCurrentAndNoncurrent
269854 usd
CY2024Q3 GHST Common Stock Payable Related Parties
CommonStockPayableRelatedParties
9559 usd
CY2024Q3 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0001079973-24-001544-index-headers.html Edgar Link pending
0001079973-24-001544-index.html Edgar Link pending
0001079973-24-001544.txt Edgar Link pending
0001079973-24-001544-xbrl.zip Edgar Link pending
ex31x1.htm Edgar Link pending
ex31x2a.htm Edgar Link pending
ex31x2b.htm Edgar Link pending
ex32x1.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
ghst-20240930.xsd Edgar Link pending
ghst_10q.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
ghst-20240930_cal.xml Edgar Link unprocessable
ghst-20240930_def.xml Edgar Link unprocessable
ghst-20240930_lab.xml Edgar Link unprocessable
ghst-20240930_pre.xml Edgar Link unprocessable
ghst_10q_htm.xml Edgar Link completed